The 12-gene assay provides additional recurrence risk information that influences physicians’ adjuvant chemotherapy recommendations in real-world clinical settings for stage II, T3, mismatch-repair-proficient (MMR-P) colon cancer patients.

Recommendation changes due to the 12-gene assay are likely to lead to both savings in direct medical costs and increased quality-adjusted survival.

Patients with lower risk of recurrence whose adjuvant treatment recommendations are changed away from adjuvant chemotherapy with the 12-gene assay avoid costly adverse events.